EXAGEN INC. (XGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
XGN POWR Grades
- Stability is the dimension where XGN ranks best; there it ranks ahead of 70.44% of US stocks.
- XGN's strongest trending metric is Sentiment; it's been moving down over the last 92 days.
- XGN ranks lowest in Growth; there it ranks in the 2nd percentile.
XGN Stock Summary
- XGN has a higher market value than just 14.9% of US stocks; more precisely, its current market capitalization is $55,486,259.
- EXAGEN INC's stock had its IPO on September 19, 2019, making it an older stock than merely 16.34% of US equities in our set.
- The volatility of EXAGEN INC's share price is greater than that of 88.07% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to EXAGEN INC are SGHT, LPRO, ECOR, CSII, and SSTK.
- Visit XGN's SEC page to see the company's official filings. To visit the company's web site, go to avisetest.com.
XGN Valuation Summary
- XGN's price/earnings ratio is -1.2; this is 105.17% lower than that of the median Healthcare stock.
- XGN's EV/EBIT ratio has moved up 41.3 over the prior 39 months.
Below are key valuation metrics over time for XGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XGN | 2022-11-25 | 1.1 | 0.9 | -1.2 | -0.4 |
| XGN | 2022-11-23 | 1.2 | 1.0 | -1.4 | -0.6 |
| XGN | 2022-11-22 | 0.9 | 0.7 | -1.0 | -0.2 |
| XGN | 2022-11-21 | 1.0 | 0.8 | -1.1 | -0.3 |
| XGN | 2022-11-18 | 1.1 | 0.7 | -1.3 | -0.1 |
| XGN | 2022-11-17 | 1.1 | 0.8 | -1.3 | -0.2 |
XGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XGN has a Quality Grade of D, ranking ahead of 19.97% of graded US stocks.
- XGN's asset turnover comes in at 0.436 -- ranking 56th of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows XGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.436 | 0.597 | -0.539 |
| 2021-03-31 | 0.457 | 0.611 | -0.455 |
| 2020-12-31 | 0.519 | 0.606 | -0.452 |
| 2020-09-30 | 0.474 | 0.575 | -0.457 |
| 2020-06-30 | 0.453 | 0.560 | -0.424 |
XGN Price Target
For more insight on analysts targets of XGN, see our XGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
XGN Stock Price Chart Interactive Chart >
XGN Price/Volume Stats
| Current price | $2.90 | 52-week high | $12.40 |
| Prev. close | $3.04 | 52-week low | $2.10 |
| Day low | $2.65 | Volume | 197,800 |
| Day high | $2.95 | Avg. volume | 54,451 |
| 50-day MA | $2.75 | Dividend yield | N/A |
| 200-day MA | $5.48 | Market Cap | 47.15M |
EXAGEN INC. (XGN) Company Bio
Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand.
Latest XGN News From Around the Web
Below are the latest news stories about EXAGEN INC that investors may wish to consider to help them evaluate XGN as an investment opportunity.
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue EstimatesExagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Exagen Inc. Reports Third Quarter 2022 ResultsMedicare Reimbursement ReturnsSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights: Total revenue of $14.7 million recognized in the third quarter of 2022. Our flagship AVISE® CTD test, including AVISE® Lupus, recognized revenue of $12.8 million in the third quarter of 2022.Delivered 35,569 AVISE CTD tests, including AVISE Lupu |
Exagen Inc. to Participate in Fourth Quarter Investor ConferencesSAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth quarter investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Thursday, November 17, 2022, at the Westin NY Grand Central Hotel Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference Panel Presentation - Diagnostics Tool Time: No |
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022. John Aballi, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT). Interested parties |
Exagen Announces Appointment of John Aballi as CEOSAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. The Exagen Board has appointed Mr. Aballi as CEO, President, and a member of the Board. Mr. Aballi is an executive with a broad range of experience in growth-stage companies in the clinical diagnostic |
XGN Price Returns
| 1-mo | 13.28% |
| 3-mo | -35.98% |
| 6-mo | -43.25% |
| 1-year | -72.85% |
| 3-year | -83.74% |
| 5-year | N/A |
| YTD | -75.06% |
| 2021 | -11.89% |
| 2020 | -48.03% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...